Academician Zhang Yun's team for 20 years to study Chinese medicine has been praised internationally

The Cardiovascular Laboratory where Academician Zhang Yun's team is located is a key laboratory of the Ministry of Education and the National Health and Health Commission's cardiovascular reconstruction and functional research. It has been continuously committed to cardiovascular reconstruction and functional research for many years.

Academician Zhang Yun recalled: "The research on Tongxinluo actually started 20 years ago." At that time, the research project carried out by the team wanted to observe what kind of known drugs could interfere with dynamic pulse -shaped sclerosis and collected through animal research through animal research. Some objective evidence, so want to find a representative Chinese medicine. At that time, Tongxinluo Capsule was found to have anti -angina pectoris, so it was selected by the team as a research object to compare research with Bintin.

The editorial department of "American Physiology" commented on Tongxinluo.

As we all know, atherosclerosis is the cause of cardiovascular disease and one of the important risk factors affecting the prognosis of patients with cardiovascular disease. As the cornerstone of anti -arteriosclerotic treatment, Jegmine drugs have achieved good results in the primary and secondary prevention of atherosclerotic cardiovascular events. However, the disadvantage of the United States is that even if the high -intensity is treated with a high -intensity of heating drugs, there are still some patients with high risk of atherosclerotic cardiovascular disease, and there are residual risks of cardiovascular events. Therefore, it is particularly important to find and verify that the drugs that can be safe and effective in treating atherosclerosis.

"Looking back now, it is still very fortunate." Academician Zhang Yun admitted that in fact, it was risky when choosing Tongxin Capsules, because we did not know if this Chinese medicine really had anti -atherosclerotic effects. Essence However, from the interest of a doctoral student, the laboratory began a scientific research and exploration of Tongxinluo capsule antiplication of anti -atherosclerosis initiated by researchers.

Interest is the best leader. The first exploration has gained a good result, and it has further triggered the interest of the team's in -depth research. Academician Zhang Yun bluntly stated that although the post -relay carried out the doctoral students of Tongxinluo Capsule research at the beginning Discovering this is a vast world.

In 2009, the paper carried out by Academician Zhang Yun's team of "Chinese Medicine Tonglin Dose and Dependence Enhanced Evil Paper Stability: Research with Large Dives of Sippedtin Treatment" was published in the full text of international authoritative medical magazine "American Physiology Magazine", The result shows that Tongxin Liao capsules can effectively reduce the volume of plaques and reduce the risk of rupture of plaques, thereby reducing the risk of myocardial infarction and cerebral infarction.

The editorial department of "American Physiology Magazine" commented on Tongxinluo. "The high -risk patients who may develop into a coronary heart disease in the future ignite the lamp of hope!" Published a study related to Chinese medicine. Starting from this article, this magazine opened the door for the study of Chinese medicine, and then received the basic research article of Professor Yang Yuejin's application of Tongxin Capsule intervention in the heart muscle. Our work not only published an article, but also opened a door to mainstream American magazines. "

Capital studies "born out of response"

The research team is not satisfied with this. On the basis of animal experiments, in order to confirm the effective clinical application of Tongxin Capsules, the research team has carried out a series of clinical research. Among them, the "clinical study of the Capital Capsule in the Capital Capsule of the Capital Capsule in the Capital Capsule of acute myocardial infarction after the treatment of the treatment of myocardium without rehabilitation", which was completed by Professor Yang Yuejin of the Chinese Academy of Medical Sciences. " The incidence of myocardial infarction after myocardial infarction has reduced the area of ​​myocardial infarction. However, at that time, the large -scale, multi -center, random, and double -blind clinical research evidence of Tongxinluo capsule anti -atherosclerosis was still lacking. Until the advent of CAPITAL research, it provided solid and powerful for atherosclerotic effects for Tongxinluo capsules to treat atheroscopy -shaped sclerosis. The evidence -based basis.

Academician Zhang Yun also talked about his original intention of "Capital" in the project name. Looking at the world, China is the "capital" of Chinese medicine. Therefore, the clinical study of Tongluo, which is completed by the Chinese team, is naturally a "Capital" study of Chinese medicine.

Therefore, in order to clarify whether the treatment of Tongxin Capsules can reduce the progress of the lattering patients with the inheritance of the sub -clinical atherosclerosis by reducing the intimal end of the neck endometrium and the area of ​​the plaque area. Leading and 35 domestic centers participated in the development of "Tongxin intervention intervention of neck, double -blindness, placebo control, multi -center clinical research (Capital Studies)".

"The design of Capital's research at that time, the team had a great determination at that time, but it was actually a great risk." For the original decision, the research was based on the treatment of his treatment. It can increase clinical benefits. It is difficult to say that the results of the study may even fail. Once failed, it may face the market for Tongxinluo. Academician Zhang Yun said that he did sweat at the time.

Kung Fu is worthy of care, and in the end Capital research has gained a surprising test result! Studies have shown that patients with clinical atherosclerosis are used to add Capital Capsules on the basis of conventional treatment, which can delay the progress of the neck endometrium thickness, plaque area and vascular reconstruction.

Academician Zhang Yun further analyzed the results of the research: "Studies can get significant results, and the team is very surprised because we test the efficacy of the increase in the basis of Tongxinluo capsules on the basis of western medicine. The incidence of cardiovascular incidents, especially instability of the patient's cardiovascular incident, is significantly reduced, which is closely related to the stability of the plaques. "In 2019, the research results of Capital research were officially published in the international authoritative science and technology journal" Nature "sub -magazine. The "Science Report" has aroused great attention and heated attention from experts and scholars at home and abroad, and has given great encouragement to researchers in the field.

On January 10, 2020, the "TCM Polarization theory Construction and the Prevention of Micro Vehicle Lessic Prevention" project based on Tongxinluo Capsule, Ginseng Yangxin Capsule, Qiqiang Qiangxin Capsule series of evidence -based medical studies also won 2019 The only first national scientific and technological progress prize in the field of life sciences. The award -winning project includes the original research results of traditional Chinese medicine theory -the system construction of traditional Chinese medicine vein theory, but also a major breakthrough in clinical study of traditional Chinese medicine and its prevention and treatment of cardiovascular and cerebrovascular diseases. In the event of the entire cardiovascular disease, related series of evidence -based medical research provides new ideas for solving clinical problems in the field of cardiovascular and cerebrovascular.

In the next step, you can consider the application of the new clinical indication certificate, that is, as long as there are plaques, you can eat Tongxin capsules. Regardless of whether the patient has asymptomatic or hyperlipidemia

After detailed analysis of the patients, it is not difficult to find that Capital studies in patients with Asian clinical cervical atherosclerosis. In this regard, Academician Zhang Yun introduced that the adaptation certificate approved by the Tongxin Capsule instructions is coronary heart disease angina pectoris and cerebral infarction, which is mainly used in the secondary prevention stage of cardiovascular and cerebrovascular diseases, but considering that it can prevent atherosclerosis The progress of plaques and stable plaques should be used for first -level prevention of cardiovascular and cerebrovascular disease.

Therefore, patients with Capital study are all sub -clinical cervical atherosclerosis patients. When these patients are at the baseline, more than 50%have a history of hypertension, more than 20%have a history of diabetes, and 4%have a history of myocardial infarction. Judging from the current evaluation standards, the patients who have been included in Capital's research are in the risk of cardiovascular disease and high -risk groups.

In addition, Academician Zhang Yun specifically mentioned that the efficacy of any effective resistance to the anemia -shaped hardening drug must be far exceeding the first -level prevention. However, among patients with clinical cervical atherosclerosis and high risk of cardiovascular disease risk, Tongxinluo Capsule treatment still achieves the result of consistency with the secondary prevention, that is, the Tongxinluo capsule can significantly reduce the patient's unstable angina pectoris of angina pectoris. The incidence and overall composite cardiovascular incidence rate is very important. Academician Zhang Yun talked: "In the next step, you can consider the application of the new clinical application of the new clinical application of Tongxinluo Capsule, that is, as long as there is a plaque, you can eat Tongxin Capsules. Regardless of whether the patient has asymptomatic or hyperlipidemia."

Twenty years of wind and rain, the blue wrapping of the road is finally successful. Academician Zhang Yun's team of devotion and continuous research has been a path of innovative development for the clinical application and internationalization of Tongxinluo capsules. In order to benefit more patients and high -risk groups, Academician Zhang Yun's team is going all out to try to clarify its mechanism.

Regarding the follow -up development of traditional Chinese medicine, Academician Zhang Yun said: "In the future, two roads need to be taken, that is, to keep positive and innovative. Shouzheng is to protect the true diagnosis of traditional Chinese medicine and conduct diagnosis and treatment according to traditional Chinese medicine ideas. Basic and clinical scientific research work, taking the road of internationalization can only develop better. "

Source: Xinzhou.com

- END -